Teresa Amaral, Vice-Chair of SAG Oncology at the European Medicines Agency, Head of Early Phase Clinical Trials, Skin Cancer and Sarcoma Program at Institute Strauss, shared a post on by ESMO – European Society for Medical Oncology on LinkedIn, adding:
“It was a pleasure to join the first day of the ESMO – European Society for Medical Oncology sarcoma and Rare Cancers Congress in Lugano.
If you are around tomorrow and want to chat, drop by the posters area. I will be there presenting our poster – 298P – Real-world antitumor activity of trastuzumab deruxtecan in rare HER2-expressing solid tumors: A monocentric case series.
For more on the emerging need to standardize tumor agnostic drug development, check out the proposed framework from ESMO Tumor-Agnostic Classifier and Screener (ETAC-S), an easily applicable set of minimum requirements to screen and claim the tumor-agnostic potential of molecularly guided treatment options (MGTOs).”
Quoting ESMO‘s post:
“A warm welcome to all delegates joining the ESMO Sarcoma and Rare Cancers Congress 2026 in Lugano.
Every rare cancer story deserves a breakthrough-powered by hope, care and action. Thank you for being part of the progress.”
Other articles about ESMO on OncoDaily.